Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
CHOLOGRAFIN SODIUM vs DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodipamide (cholografin sodium) is a radiographic contrast agent that opacifies the biliary ducts and gallbladder by being excreted into bile via the hepatic organic anion transporter (OATP) and then concentrated in the gallbladder. It absorbs X-rays due to its iodine content, allowing visualization of the biliary tree.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
2-3 mL of 30% solution intravenously over 1-2 minutes, repeated if necessary up to a total of 10 mL.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In severe renal impairment (CrCl < 30 mL/min), half-life may extend to 10-20 hours, requiring dose adjustment.
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Primarily renal excretion via glomerular filtration and tubular secretion. Approximately 70-80% of the dose is excreted unchanged in urine within 24 hours. Biliary excretion accounts for less than 10%, with fecal elimination minimal.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent